Effets indésirables liés au système immunitaire (irEI) chez les patients atteints de spondylarthrite ankylosante (SA) traités par des inhibiteurs de l'interleukine (IL)-17 : étude systématique et méta-analyse
Inflammopharmacology. 2022, Apr;30(2):435-451. doi: 10.1007/s10787-022-00933-z
The most common immune system-related AEs in patients treated with IL-17 inhibitors are mucosal and opportunistic infections.
Interleukin (IL)-17 inhibitors are a series of biological drugs used to treat a number of conditions, including ankylosing spondylitis, a disease characterised by immune system dysregulation and joint inflammation. Azadeh, et al. aimed to assess the risk of immune system-related AEs due to targeting IL-17 or IL-17R.